Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
Results show the potential of a real-time, non-invasive blood test to quantify…
Wytec Announces Response to RFP With the North Texas Council of Governments in Providing Gunshot Detection for 1,207 Texas ISDs
SAN ANTONIO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Wytec (OTCQB:WYTC) has announced…